Characteristics of the patients in the Bridging ITP trial
| . | Eltrombopag (n = 38) . | Intravenous immunoglobulin (n = 36) . |
|---|---|---|
| Recruitment site | ||
| Ontario | 32 (84.2%) | 31 (86.1%) |
| Alberta | 2 (5.3%) | 0 |
| Quebec | 4 (10.5%) | 5 (13.9%) |
| Females | 20 (53%) | 18 (50%) |
| Age, median (IQR) | 64 (50-73.3) | 63.5 (56-74.5) |
| Weight in kgs, median (IQR) | 84 (69.8-102.6) | 81.7 (68-93.6) |
| Immune thrombocytopenia | ||
| Secondary | 4 (11%) | 5 (14%) |
| Chronic | 29 (76%) | 29 (81%) |
| Duration in years | 8 (1.2-13.7) | 5.6 (1.8-15.1) |
| Surgery classification | ||
| Major | 17 (45%) | 14 (39%) |
| Minor | 21 (55%) | 22 (61%) |
| . | Eltrombopag (n = 38) . | Intravenous immunoglobulin (n = 36) . |
|---|---|---|
| Recruitment site | ||
| Ontario | 32 (84.2%) | 31 (86.1%) |
| Alberta | 2 (5.3%) | 0 |
| Quebec | 4 (10.5%) | 5 (13.9%) |
| Females | 20 (53%) | 18 (50%) |
| Age, median (IQR) | 64 (50-73.3) | 63.5 (56-74.5) |
| Weight in kgs, median (IQR) | 84 (69.8-102.6) | 81.7 (68-93.6) |
| Immune thrombocytopenia | ||
| Secondary | 4 (11%) | 5 (14%) |
| Chronic | 29 (76%) | 29 (81%) |
| Duration in years | 8 (1.2-13.7) | 5.6 (1.8-15.1) |
| Surgery classification | ||
| Major | 17 (45%) | 14 (39%) |
| Minor | 21 (55%) | 22 (61%) |
IQR, interquartile range.